NO20056174L - Levering av et aktivt legemiddel til den posteriore del av oyet via subkonjunktiv eller periokular levering av et prolegemiddel - Google Patents

Levering av et aktivt legemiddel til den posteriore del av oyet via subkonjunktiv eller periokular levering av et prolegemiddel

Info

Publication number
NO20056174L
NO20056174L NO20056174A NO20056174A NO20056174L NO 20056174 L NO20056174 L NO 20056174L NO 20056174 A NO20056174 A NO 20056174A NO 20056174 A NO20056174 A NO 20056174A NO 20056174 L NO20056174 L NO 20056174L
Authority
NO
Norway
Prior art keywords
delivery
active drug
periocular
prodrug
posterior portion
Prior art date
Application number
NO20056174A
Other languages
English (en)
Norwegian (no)
Inventor
Orest Olejnik
Patrick M Hughes
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of NO20056174L publication Critical patent/NO20056174L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20056174A 2003-07-10 2005-12-23 Levering av et aktivt legemiddel til den posteriore del av oyet via subkonjunktiv eller periokular levering av et prolegemiddel NO20056174L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/617,468 US20050009910A1 (en) 2003-07-10 2003-07-10 Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
PCT/US2004/021938 WO2005011741A2 (fr) 2003-07-10 2004-07-07 Administration d'un medicament actif dans la partie posterieure de l'oeil, via adminstration sous-conjonctivale ou perioculaire d'un promedicament

Publications (1)

Publication Number Publication Date
NO20056174L true NO20056174L (no) 2006-01-25

Family

ID=33564972

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20056174A NO20056174L (no) 2003-07-10 2005-12-23 Levering av et aktivt legemiddel til den posteriore del av oyet via subkonjunktiv eller periokular levering av et prolegemiddel

Country Status (16)

Country Link
US (2) US20050009910A1 (fr)
EP (1) EP1644047A2 (fr)
JP (1) JP2007528851A (fr)
KR (1) KR20060033008A (fr)
CN (1) CN1882362A (fr)
AU (1) AU2004260645B2 (fr)
BR (1) BRPI0412496A (fr)
CA (1) CA2531753A1 (fr)
IL (1) IL172583A (fr)
MX (1) MXPA06000408A (fr)
NO (1) NO20056174L (fr)
NZ (2) NZ582376A (fr)
PL (1) PL380169A1 (fr)
RU (1) RU2353393C2 (fr)
WO (1) WO2005011741A2 (fr)
ZA (1) ZA200510129B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
JP2007513161A (ja) * 2003-12-02 2007-05-24 アラーガン、インコーポレイテッド レチノイドによる光受容体の変性の予防および／または減少
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
EP1727529B1 (fr) 2004-03-17 2016-03-02 Lars Michael Larsen Prevention de la retinopathie par inhibition du cycle visuel
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
BRPI0510485A (pt) 2004-04-30 2007-11-13 Allergan Inc implantes inibidores de tirosina cinase intravìtreos biodegradáveis
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
AU2005240078A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
AU2011211380B9 (en) * 2004-04-30 2014-05-08 Allergan, Inc. Biodegradable intravitreal tyrosine kinase inhibitor implants
WO2006043965A1 (fr) * 2004-10-14 2006-04-27 Allergan, Inc. Compositions ophtalmiques therapeutiques contenant des excipients sans danger pour la retine et leurs methodes
US8246949B2 (en) * 2004-10-27 2012-08-21 Aciont, Inc. Methods and devices for sustained in-vivo release of an active agent
WO2007130134A2 (fr) * 2005-12-02 2007-11-15 (Osi) Eyetech, Inc. Microparticules à libération contrôlée
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US8197435B2 (en) 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
PL2322183T3 (pl) * 2006-06-01 2015-01-30 Santen Sas Wykorzystanie proleku do podawania doocznego, śródszklistkowego
MX2011012233A (es) 2009-05-20 2012-04-19 Ranbaxy Lab Ltd Soluciones de retinoide topicas.
US10022348B2 (en) 2009-05-20 2018-07-17 Sun Pharmaceutical Industries Limited Topical solution of isotretinoin
CA2791278C (fr) 2010-02-25 2015-11-24 The Johns Hopkins University Delivrance prolongee d'agents therapeutiques a un compartiment oculaire
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
JP5996544B2 (ja) 2010-10-15 2016-09-21 クリアサイド・バイオメディカル・インコーポレーテッドＣｌｅａｒｓｉｄｅ Ｂｉｏｍｅｄｉｃａｌ Ｉｎｃｏｒｐｏｒａｔｅｄ 眼球アクセス用装置
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
US9415020B2 (en) 2012-01-19 2016-08-16 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
AU2013232297B2 (en) 2012-03-16 2016-01-14 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
WO2013138346A1 (fr) 2012-03-16 2013-09-19 The Johns Hopkins University Conjugués copolymère multi-blocs non linéaire-médicament pour l'administration de principes actifs
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US10688041B2 (en) 2012-05-03 2020-06-23 Kala Pharmaceuticals, Inc. Compositions and methods utilizing poly(vinyl alcohol) and/or other polymers that aid particle transport in mucus
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
JP6360039B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
EP2849728A1 (fr) 2012-05-04 2015-03-25 The Johns Hopkins University Véhicules de médicament à base de lipide pour pénétration rapide à travers les revêtements de mucus
KR20210133321A (ko) 2012-11-08 2021-11-05 클리어사이드 바이오메디컬, 인코포레이드 인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치
WO2014124006A1 (fr) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticules pour le suivi de l'imagerie par résonance magnétique et procédés de fabrication et d'utilisation associés
EP4378444A3 (fr) 2013-05-03 2024-07-03 Clearside Biomedical, Inc. Appareil et procédés d'injection oculaire
EP3003454B1 (fr) 2013-06-03 2020-01-08 Clearside Biomedical, Inc. Appareil pour une administration de médicament à l'aide de multiples réservoirs
US10010447B2 (en) 2013-12-18 2018-07-03 Novartis Ag Systems and methods for subretinal delivery of therapeutic agents
WO2015116709A1 (fr) 2014-01-28 2015-08-06 Allergan, Inc. Formulations topiques de rétinoïdes, et procédés d'utilisation
WO2015127389A1 (fr) 2014-02-23 2015-08-27 The Johns Hopkins University Formulations de lavement hypotonique et méthodes d'utilisation
CN106794321A (zh) 2014-06-20 2017-05-31 科尼尔赛德生物医学公司 可变直径插管以及用于控制对药剂递送的插入深度的方法
WO2016123125A1 (fr) 2015-01-27 2016-08-04 The Johns Hopkins University Formulations d'hydrogel hypotoniques pour le transport amélioré d'agents actifs au niveau de surfaces muqueuses
EP3340982B1 (fr) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Composés pour le traitement de troubles immunitaires et inflammatoires
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3413851B1 (fr) 2016-02-10 2023-09-27 Clearside Biomedical, Inc. Emballage
EP3452165A1 (fr) 2016-05-02 2019-03-13 Clearside Biomedical, Inc. Systèmes et méthodes pour l'administration de médicaments par voie ophtalmique
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
WO2017197036A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères spirocycliques pour la dégradation de protéines cibles
WO2018005552A1 (fr) 2016-06-27 2018-01-04 Achillion Pharmaceuticals, Inc. Composés de quinazoline et d'indole destinés au traitement de troubles médicaux
RU2019102647A (ru) 2016-07-01 2020-08-03 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
IL305537A (en) 2016-08-12 2023-10-01 Clearside Biomedical Inc Devices and methods for adjusting the insertion depth of a drug administration needle
WO2018160889A1 (fr) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Composés pharmaceutiques aryle, hétéroaryles et hétérocycliques pour le traitement de troubles médicaux
WO2018204515A1 (fr) 2017-05-02 2018-11-08 Georgia Tech Research Corporation Procédés d'administration ciblée de médicament au moyen d'une microaiguille
TW201906635A (zh) * 2017-07-04 2019-02-16 日商第一三共股份有限公司 伴隨視細胞變性的視網膜變性的疾病用藥
EP3773576A4 (fr) 2018-03-26 2021-12-29 C4 Therapeutics, Inc. Liants de céréblon pour la dégradation d'ikaros
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
JP7504088B2 (ja) 2018-10-16 2024-06-21 ジョージア ステイト ユニバーシティー リサーチ ファウンデーション インコーポレイテッド 医学的障害の治療のための一酸化炭素プロドラッグ

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5275820A (en) * 1990-12-27 1994-01-04 Allergan, Inc. Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
US5384333A (en) * 1992-03-17 1995-01-24 University Of Miami Biodegradable injectable drug delivery polymer
US5178635A (en) * 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
WO1995003009A1 (fr) * 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Methode de traitement de la degenerescence maculaire
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5420120A (en) * 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
EP0754046A1 (fr) * 1994-04-04 1997-01-22 FREEMAN, William R. Emploi de nucleosides de phosphonylemethoxyalkyle pour traiter la pression intra-oculaire elevee
JP4259610B2 (ja) * 1994-04-08 2009-04-30 キューエルティー・ユーエスエイ・インコーポレーテッド 液体デリバリー組成物
US5824685A (en) * 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5718922A (en) * 1995-05-31 1998-02-17 Schepens Eye Research Institute, Inc. Intravitreal microsphere drug delivery and method of preparation
US5675033A (en) * 1995-06-06 1997-10-07 Allergan 2,4-pentadienoic acid derivatives having retinoid-like biological activity
AU752225B2 (en) * 1998-07-17 2002-09-12 Pacira Pharmaceuticals, Inc. Biodegradable compositions for the controlled release of encapsulated substances
US6017938A (en) * 1998-07-28 2000-01-25 Bershad; Susan Short contact treatment for acne
US6378526B1 (en) * 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US6489335B2 (en) * 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
AU2001268159B2 (en) * 2000-06-02 2005-09-15 Eisai Inc. Delivery systems for bioactive agents
AR030346A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
JP4061015B2 (ja) * 2000-10-30 2008-03-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 レチノイン酸レセプターアゴニスト作用を有する薬剤含有組成物
US6673802B2 (en) * 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
KR20040005936A (ko) * 2001-04-26 2004-01-16 컨트롤 딜리버리 시스템즈 인코포레이티드 공동약물을 함유하는 서방 약물 전달 시스템
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US7381426B2 (en) * 2002-01-24 2008-06-03 Southwest Research Institute Targeted delivery of bioactive factors to the systemic skeleton
WO2004028477A2 (fr) * 2002-09-29 2004-04-08 Surmodics, Inc. Procede d'administration sub-retinienne d'agents therapeutiques comprenant des steroides, procede servant a concentrer une action pharmacodynamique au niveau de la choroide et de la retine et procedes associes servant a traiter et/ou a prevenir des maladies retiniennes

Also Published As

Publication number Publication date
WO2005011741A2 (fr) 2005-02-10
JP2007528851A (ja) 2007-10-18
CN1882362A (zh) 2006-12-20
RU2006104983A (ru) 2006-06-27
US20120157499A1 (en) 2012-06-21
IL172583A0 (en) 2006-04-10
AU2004260645A1 (en) 2005-02-10
ZA200510129B (en) 2007-02-28
AU2004260645B2 (en) 2010-03-11
CA2531753A1 (fr) 2005-02-10
IL172583A (en) 2011-02-28
RU2353393C2 (ru) 2009-04-27
WO2005011741A3 (fr) 2005-04-14
EP1644047A2 (fr) 2006-04-12
BRPI0412496A (pt) 2006-09-19
US20050009910A1 (en) 2005-01-13
NZ544027A (en) 2010-07-30
KR20060033008A (ko) 2006-04-18
NZ582376A (en) 2012-02-24
PL380169A1 (pl) 2007-01-08
MXPA06000408A (es) 2006-03-17

Similar Documents

Publication Publication Date Title
NO20056174L (no) Levering av et aktivt legemiddel til den posteriore del av oyet via subkonjunktiv eller periokular levering av et prolegemiddel
TW200633709A (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
BRPI0819081A8 (pt) Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento
GT200000184A (es) Composiciones para facilitar el crecimiento de la piel y metodos y articulos que la emplean.
BR0309623A (pt) Agentes que regulam. inibem ou modulam a atividade e/ou a expressão do fator de crescimento de tecido conjuntivo (ctgf) como um único meio de diminuir a pressão intraocular e tratar retinopatias glaucomatosas/neuropatias ópticas
WO2007046083A3 (fr) Compositions pour le traitement de maladies oculaires
NO20076245L (no) Anvendelse av TFPI for a behandle alvorlige bakterieinfeksjoner
WO2002009702A8 (fr) Methode de reduction de la pression intraoculaire avec des derives d'indole
ATE525084T1 (de) Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus
EA202190308A1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
MX2023007027A (es) Derivado de cannabinoide como compuesto farmaceuticamente activo y metodo de preparacion del mismo.
WO2022192594A3 (fr) Molécules d'acide nucléique et vaccins les comprenant pour la prévention et le traitement d'infections à coronavirus et de maladie
AU2017261303A1 (en) Ophthalmic compositions
EA202000347A1 (ru) ПРОТИВО-SARS-CoV-2 ВИРУСНОЕ СРЕДСТВО АНТИПРОВИР
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
EP3085371A1 (fr) Dérivés de parthénolide et leur utilisation dans le traitement de lésions axoniques
Hanada et al. Evaluation of the effect of tranilast on rats with spinal cord injury
WO2019010301A8 (fr) Traitement de cardiopathies par inhibition de l'action des protéines d'ancrage aux protéines kinases a (makap) du muscle
AU2020299145A8 (en) Compositions and methods for treating eye diseases
BR112023023702A2 (pt) Métodos de tratamento da cistite intersticial/síndrome da dor na bexiga
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
EA200702534A1 (ru) Применение бензоильного производного 3-аминокарбазола для лечения расстройства, связанного с продукцией простагландина e2(pge2)
MY145266A (en) Pharmaceutical use of cox-2 inhibitors in angiogenesis-mediated ocular disorders
RU2343885C1 (ru) Способ лечения субэпителиального флера роговицы после фоторефракционной кератэктомии
RU2703306C1 (ru) Способ повышения зрительных функций при эндовитреальной хирургии регматогенной отслойки сетчатки

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application